Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1997 1
2003 1
2004 2
2005 5
2006 2
2007 2
2008 5
2009 6
2010 3
2011 5
2012 5
2013 2
2014 5
2015 10
2016 11
2017 17
2018 14
2019 12
2020 19
2021 24
2022 23
2023 28
2024 30
2025 40
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 20Peppen, 20RP, 5BAuthor
Page 1
Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands.
Bels JLM, Thiessen S, van Gassel RJJ, Beishuizen A, De Bie Dekker A, Fraipont V, Lamote S, Ledoux D, Scheeren C, De Waele E, van Zanten ARH, Bormans-Russell L, van Bussel BCT, Dictus MMJ, Fivez T, Harks I, van der Horst ICC, Jonckheer J, Marechal H, Massion PB, Meex I, Paulus MC, Rinket M, van Santen S, Tartaglia K, Deane AM, Demuydt F, Puthucheary Z, Vloet LCM, Weijs PJM, van Kuijk SMJ, van de Poll MCG, Mesotten D; PRECISe study team. Bels JLM, et al. Lancet. 2024 Aug 17;404(10453):659-669. doi: 10.1016/S0140-6736(24)01304-7. Lancet. 2024. PMID: 39153816 Free article. Clinical Trial.
The primary outcome was EuroQoL 5-Dimension 5-level (EQ-5D-5L) health utility score at 30 days, 90 days, and 180 days after randomisation, adjusted for baseline EQ-5D-5L health utility score. ...FINDINGS: Between Nov 19, 2020, and April 14, 2023, 935 patients were r …
The primary outcome was EuroQoL 5-Dimension 5-level (EQ-5D-5L) health utility score at 30 days, 90 days, and 180 days after randomisa …
Evaluation of Quality of Life After Nonoperative or Operative Management of Proximal Femoral Fractures in Frail Institutionalized Patients: The FRAIL-HIP Study.
Loggers SAI, Willems HC, Van Balen R, Gosens T, Polinder S, Ponsen KJ, Van de Ree CLP, Steens J, Verhofstad MHJ, Zuurmond RG, Van Lieshout EMM, Joosse P; FRAIL-HIP Study Group. Loggers SAI, et al. JAMA Surg. 2022 May 1;157(5):424-434. doi: 10.1001/jamasurg.2022.0089. JAMA Surg. 2022. PMID: 35234817 Free PMC article.
MAIN OUTCOMES AND MEASURES: The primary outcome was the EuroQol 5 Dimension 5 Level (EQ-5D) utility score by proxies and caregivers. Secondary outcome measures were QUALIDEM (a dementia-specific quality-of-life instrument for persons with dementia in residential settings) …
MAIN OUTCOMES AND MEASURES: The primary outcome was the EuroQol 5 Dimension 5 Level (EQ-5D) utility score by proxies and caregivers. …
Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial.
Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, Maingi M, Tjandrawidjaja MC, Heffernan M, Zia MI, Porepa L, Panju M, Thabane L, Graham ID, Haynes RB, Haughton D, Simek KD, Ko DT, Connolly SJ. Van Spall HGC, et al. JAMA. 2019 Feb 26;321(8):753-761. doi: 10.1001/jama.2019.0710. JAMA. 2019. PMID: 30806695 Free PMC article. Clinical Trial.
Secondary outcomes were B-PREPARED score for discharge preparedness (range: 0 [most prepared] to 22 [least prepared]); the 3-Item Care Transitions Measure (CTM-3) for quality of transition (range: 0 [worst transition] to 100 [best transition]); the 5-level EQ-5D version (E …
Secondary outcomes were B-PREPARED score for discharge preparedness (range: 0 [most prepared] to 22 [least prepared]); the 3-Item Care Trans …
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Waterhouse DM, et al. Lung Cancer. 2024 Oct;196:107921. doi: 10.1016/j.lungcan.2024.107921. Epub 2024 Aug 6. Lung Cancer. 2024. PMID: 39303400 Free article. Clinical Trial.
Validated questionnaires captured patients' perception of their QOL and symptom burden for key secondary and exploratory PRO endpoints, including the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Quality-of-li …
Validated questionnaires captured patients' perception of their QOL and symptom burden for key secondary and exploratory PRO endpoints, incl …
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A. Pothuri B, et al. Gynecol Oncol. 2024 May;184:168-177. doi: 10.1016/j.ygyno.2024.01.021. Epub 2024 Feb 6. Gynecol Oncol. 2024. PMID: 38325276 Free article. Clinical Trial.
HRQoL was assessed as a prespecified secondary end point using patient-reported responses to the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30), the EORTC QLQ Ovarian Cancer Module (EORTC QLQ-OV28), the Functional Assessment of Cancer …
HRQoL was assessed as a prespecified secondary end point using patient-reported responses to the European Organisation for Research and Trea …
3-Benzyl-6-isopropyl-5-phen-oxy-3H-1,2,3-triazolo[4,5-d]pyrimidin-7(6H)-one.
Deng SH, Wang HM, Chen P, Ma JK, Cao FJ. Deng SH, et al. Acta Crystallogr Sect E Struct Rep Online. 2009 Oct 17;65(Pt 11):o2730-1. doi: 10.1107/S160053680904118X. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21578326 Free PMC article.
The ring system forms dihedral angles of 68.37 (10) and 71.57 (9) with the phenyl rings. The crystal packing is stabilized by van der Waals inter-actions and intermolecular C-H pi interactions....
The ring system forms dihedral angles of 68.37 (10) and 71.57 (9) with the phenyl rings. The crystal packing is stabilized by van de …
Five-Year Longitudinal Follow-Up of Restorative Neurostimulation Shows Durability of Effectiveness in Patients With Refractory Chronic Low Back Pain Associated With Multifidus Muscle Dysfunction.
Gilligan C, Volschenk W, Russo M, Green M, Gilmore C, Mehta V, Deckers K, De Smedt K, Latif U, Sayed D, Georgius P, Gentile J, Mitchell B, Langhorst M, Huygen F, Baranidharan G, Patel V, Mironer E, Ross E, Carayannopoulos A, Hayek S, Gulve A, Van Buyten JP, Tohmeh A, Fischgrund J, Lad S, Ahadian F, Deer T, Klemme W, Rauck R, Rathmell J, Maislin G, Heemels JP, Eldabe S. Gilligan C, et al. Neuromodulation. 2024 Jul;27(5):930-943. doi: 10.1016/j.neurom.2024.01.006. Epub 2024 Mar 12. Neuromodulation. 2024. PMID: 38483366 Free article. Clinical Trial.
Low back pain intensity (10-cm visual analog scale [VAS]), disability (Oswestry Disability Index), and quality of life (EuroQol's "EQ-5D-5L" index) were compared with baseline and following the intent-to-treat principle, with a supporting mixed-effects model for repeated m …
Low back pain intensity (10-cm visual analog scale [VAS]), disability (Oswestry Disability Index), and quality of life (EuroQol's "EQ-5D …
The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction.
Mourmans SGJ, Achten A, Hermans R, Scheepers MJE, D'Alessandro E, Swennen G, Woudstra J, Appelman Y, Goor HV, Schalkwijk C, Knackstedt C, Weerts J, Eringa EC, van Empel VPM. Mourmans SGJ, et al. Cardiovasc Diabetol. 2025 Apr 25;24(1):182. doi: 10.1186/s12933-025-02679-8. Cardiovasc Diabetol. 2025. PMID: 40281528 Free PMC article. Clinical Trial.
Secondarily we investigated quality-of-life based on the EQ-5D-5 L questionnaire at baseline and follow-up. RESULTS: Twenty six patients finished the study according to protocol (mean age of 74 7 years, 62% female). ...
Secondarily we investigated quality-of-life based on the EQ-5D-5 L questionnaire at baseline and follow-up. RESULTS: Twenty six patie …
[68Ga]FAPI PET/CT reveals increased pulmonary fibroblast activation protein expression in long COVID patients after ICU discharge.
van Leer B, Londema M, Kasalak Ö, van Snick JH, Duiverman ML, Kuijvenhoven JC, de Kruif MD, Oprea-Lager DE, Pabst K, Hellemons ME, Boersma HH, Prokop M, Nijsten MW, Glaudemans AWJM, Pillay J, Slart RHJA; COVID-CLIMATE consortium. van Leer B, et al. Eur J Nucl Med Mol Imaging. 2025 Dec;53(1):565-573. doi: 10.1007/s00259-025-07376-y. Epub 2025 Jun 21. Eur J Nucl Med Mol Imaging. 2025. PMID: 40542858 Free PMC article.
A [(68)Ga]FAPI PET/CT scan was performed including a high-resolution CT scan, lung function test, EQ-5D questionnaire, 6 min walking test and inflammatory markers. Age and sex-matched subjects, without pulmonary pathology, served as controls. ...
A [(68)Ga]FAPI PET/CT scan was performed including a high-resolution CT scan, lung function test, EQ-5D questionnaire, 6 min walking …
Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF.
Yang M, Henderson AD, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Rouleau JL, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Rizkala A, Lewis EF, Jhund PS, Solomon SD, McMurray JJV. Yang M, et al. Eur Heart J Cardiovasc Pharmacother. 2025 Nov 4;11(7):574-589. doi: 10.1093/ehjcvp/pvaf064. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 40839760 Free PMC article. Clinical Trial.
AIMS: To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and the effect of sacubitril/valsartan on this score using patient-level data from the PARADIGM- …
AIMS: To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or …
241 results